These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7067621)

  • 21. Prospective comparison of cefoxitin and cefazolin in infections caused by aerobic bacteria.
    Gurwith M; Albritton W; Lank B; Harding G; Ronald A
    Antimicrob Agents Chemother; 1978 Feb; 13(2):255-60. PubMed ID: 348096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infections due to endemic, multiply resistant gram-negative rods: sensitivity to and therapy with cefoxitin.
    Alford RH
    Rev Infect Dis; 1979; 1(1):175-82. PubMed ID: 400932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefoxitin plus tobramycin and clindamycin plus tobramycin. A prospective randomized comparison in the therapy of mixed aerobic/anaerobic infections.
    Nicolle LE; Harding GK; Louie TJ; Thomson MJ; Blanchard RJ
    Arch Surg; 1986 Aug; 121(8):891-6. PubMed ID: 3524511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefamandole and cefoxitin.
    Sanders CV; Greenberg RN; Marier RL
    Ann Intern Med; 1985 Jul; 103(1):70-8. PubMed ID: 3890658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical findings of cefoxitin in the treatment of obstetric and gynecological infections (author's transl)].
    Hayasaki M; Iwasa SU; Noda K; Yamada Y; Ito K; Iida M; Chin C
    Jpn J Antibiot; 1982 Jan; 35(1):189-201. PubMed ID: 7069930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical use of cefoxitin, a new semisynthetic cephamycin.
    Little PJ; Peddie BA
    N Z Med J; 1978 Jul; 88(616):46-9. PubMed ID: 279853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost comparison of two antimicrobial regimens for treating mixed aerobic-anaerobic infections.
    Scheife RT; Tally FP; McGowan K; Gorbach SL
    Am J Hosp Pharm; 1981 Oct; 38(10):1466-9. PubMed ID: 7294038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro and in-vivo comparison of mezlocillin and cefoxitin.
    LeFrock JL; Molavi A; Rolston K; Smith B; Schell R; Chandrasekar P; Carr B
    J Antimicrob Chemother; 1983 May; 11 Suppl C():83-90. PubMed ID: 6352609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of significant bacterial infections in adults with cefoxitin.
    Ribner BS; Billiard BS; Freimer EH
    Rev Infect Dis; 1979; 1(1):152-7. PubMed ID: 318216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of cefmenoxime versus cefoxitin in serious infections.
    Bechard DL; Hawkins SH; Sutherland SC
    Am J Med; 1984 Dec; 77(6A):13-6. PubMed ID: 6097117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of serious obstetric and gynecologic infections with cefoxitin.
    Hager WD; McDaniel PS
    J Reprod Med; 1983 May; 28(5):337-40. PubMed ID: 6152988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of cefoxitin in treatment of infections in 47 orthopedic patients.
    Schurman DJ; Dillingham M
    Rev Infect Dis; 1979; 1(1):206-9. PubMed ID: 318224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical studies of cefoxitin for infectious diseases in the field of obstetrics and gynecology (author's transl)].
    Endo H; Ota S; Ikeno N; Watanabe M; Shima I; Takahashi K
    Jpn J Antibiot; 1981 Jul; 34(7):1052-7. PubMed ID: 7321182
    [No Abstract]   [Full Text] [Related]  

  • 34. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
    Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
    Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and bacteriological evaluation of cefoxitin therapy in children.
    Jacobson JA; Santos JI; Palmer WM
    Antimicrob Agents Chemother; 1979 Aug; 16(2):183-5. PubMed ID: 485129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitroimidazoles: in vitro activity and efficacy in anaerobic infections.
    Tally FP; Goldin B; Sullivan NE
    Scand J Infect Dis Suppl; 1981; 26():46-53. PubMed ID: 6941456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefmenoxime. Clinical, bacteriologic, and pharmacologic studies.
    LeFrock JL; Molavi A; McCloskey RV; Rolston K; Chandrasekar P; Henao L; Smith BR; Kannangara W; Schell RF; Carr BB
    Am J Med; 1984 Jul; 77(1):72-8. PubMed ID: 6331163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefoxitin and cephamycins: microbiological studies.
    Stapley EO; Birnbaum J; Miller AK; Wallick H; Hendlin D; Woodruff HB
    Rev Infect Dis; 1979; 1(1):73-89. PubMed ID: 400941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of infections in hospitalized patients with ticarcillin plus clavulanic acid. A comparative study.
    Holloway WJ
    Am J Med; 1985 Nov; 79(5B):168-71. PubMed ID: 4073086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Experience with cefoxitin in intensive care surgical departments].
    Mingolla F; Feliciotti F
    Chir Ital; 1982 Jun; 34(3):404-16. PubMed ID: 7105270
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.